Hatziapostolou M, Polytarchou C
Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Br J Pharmacol. 2015 Sep;172(18):4597-4599. doi: 10.1111/bph.12718.
This article is a Commentary on Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195-5208. doi: 10.1111/bph.12669.
本文是对哈桑 - 穆罕默德一世、乔治·C、因塞尔蒂·M、鲁索·S、帕拉·D、帕斯夸莱·E·B、扎诺蒂·I、维奇尼·P、巴罗切利·E、里瓦拉·S、莫尔·M、洛多拉·A和托尼奥利尼·M(2014年)所著文章的评论。《UniPR129是一种竞争性小分子Eph - 促红细胞生成素受体拮抗剂,在低微摩尔浓度下可阻断体外血管生成》。《英国药理学期刊》171卷:5195 - 5208页。doi: 10.1111/bph.12669 。